GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
Monday, November 19, 2018 09:50 AM

Combined Technologies May Yield Therapies for Multiple Cancer Indications 

ATLANTA, GA, - (NewMediaWire) - November 19, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with Leidos, Inc. on a research program evaluating the combination of the companies’ respective technologies. The project will include the design, construction, and characterization of multiple immunotherapeutic vaccine candidates using GeoVax’s MVA-VLP vaccine platform combined with certain novel peptide PD-1 checkpoint inhibitors developed by Leidos. The vaccine design, construction, and characterization will be performed at GeoVax with further analysis conducted by Leidos. 
GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.

Read more...
 
Georgia Bio Welcomes Kristina Forbes as Senior Director of Member Engagement
Thursday, November 15, 2018 05:57 PM

The board and staff of Georgia Bio are delighted to announce the newest member of our team: Kristina Forbes, who officially joined Georgia Bio as our full-time Senior Director of Member Engagement.  This newly created role will increase the depth of Georgia Bio’s collaboration with our members as we continue to amplify learning and engagement across our community, and strengthen the voice of life sciences in Georgia.

“Kristina’s role will enable Georgia Bio to keep its finger on the pulse of our growing membership, as we continue to inform and strengthen the voice of Georgia’s innovative biotech, medtech and digital health sectors,” said Maria Thacker Goethe, Georgia Bio’s Acting President and CEO.  “We trust her passion for and commitment to member engagement, community growth, and partner development will serve her well as a member of the Georgia Bio team.” 

Kristina comes to Georgia Bio with a depth of experience in association management and member engagement, in her role as Director of Business Development for the Technology Association of Georgia (TAG).  There, her work focused on expanding the TAG network and onboarding new members. Kristina brings with her a rich background across a spectrum of community engagement initiatives and organizations that we are sure will help to provide more value to members and growth of the sector. 

She achieved her bachelor’s degree in Psychology from the University of Georgia and was raised in Alpharetta. In addition to her work at TAG, Kristina previously worked with the Boy Scouts of America and Chi Phi Educational Trust, bringing more than sixyears of experience in non-profit membership and fundraising. Kristina lives in Midtown Atlanta and has been a volunteer member of Rotary International, Cobb County Chamber of Commerce, Delta Gamma and Children’s Healthcare of Atlanta. In her spare time, she enjoys spending time with her dog and baking apple pies.

Kristina may be reached at [email protected]or 404-920-2043.

 
GeoVax and Virometix to Collaborate on Immunotherapy Program for HPV Infections and Related Cancers
Tuesday, November 13, 2018 01:00 PM

GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology

Atlanta, GA - (NewMediaWire) - November 13, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, and Virometix AG, a company developing next-generation Synthetic Virus-Like Particle (SVLPTM) based vaccines, announced today the start of a collaboration to develop a therapeutic vaccine for human papillomavirus (HPV) infection. The collaboration will include preclinical animal testing of GeoVax’s MVA-vectored HPV vaccine candidates in combination with Virometix’ synthetic HPV vaccine candidate.

GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination induces two pools of antigens as targets for the immune response – virus-infected cells and released multimeric or VLP proteins. This strategy mimics a natural viral infection, triggering the body to produce a robust and durable immune response with involvement of both antibodies and T cells.

Read more...
 
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
Tuesday, November 06, 2018 10:44 AM

ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that the primary endpoint was not achieved in its Phase 3 clinical trial (“SAPPHIRE”) investigating the superiority of XIPERE (formerly “suprachoroidal CLS-TA”) used together with the intravitreal anti-VEGF agent EYLEA® (aflibercept) (“intravitreal Eylea”), compared to intravitreal Eylea monotherapy, for the treatment of retinal vein occlusion (‘RVO”).  The primary endpoint of this trial was the proportion of patients in the combination treatment arm, compared to the intravitreal Eylea-alone control arm, with improvements in best corrected visual acuity (“BCVA”) from baseline of at least 15 letters on the Early Treatment Diabetic Retinopathy Study (“ETDRS”) scale at eight weeks after initial treatment.

“In the SAPPHIRE trial, approximately 50% of patients in both arms showed at least a 15 letter improvement in vision; unfortunately, there was no additional benefit for patients receiving XIPERE together with intravitreal Eylea,” said Daniel White, Chief Executive Officer and President of Clearside.  “In light of these 8-week topline data, we plan to discontinue clinical development of combination therapy for RVO, which includes SAPPHIRE and its companion Phase 3  clinical trial, TOPAZ.”

Read more...
 
Oncology Analytics Moves Corporate Headquarters to Atlanta
Tuesday, November 06, 2018 10:44 AM

ATLANTA, October 31, 2018 – Oncology Analytics, a leading technology-enabled service company which provides health plans, providers and patients with an evidence-based, analytics focused approach to utilization management that is purpose-built for oncology, announced today it is expanding its operation by moving its corporate headquarters to Atlanta, Georgia.

“Atlanta is a mecca for organizations focused on cutting edge technology and breakthrough research and innovation in cancer treatments,” said Rick Dean, CEO of Oncology Analytics. “Driving the nexus of technology and patient care is fundamental to our company’s mission. We want to be part of a dynamic, forward thinking business community that shares this vision.”

Oncology Analytics provides the critical missing link for health plans in being able to manage the total cost of cancer care – which is access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, to provide their members with the ability to achieve the best possible outcomes.

Founded in Plantation, FL by Dr. Marc Fishman, a hematologist, oncologist and patient advocate, Oncology Analytics will continue to retain an active presence there. The company’s new corporate headquarters will be located at 7000 Central Parkway in the vibrant Perimeter District of Atlanta, home to over 5,000 companies.

“Having our corporate headquarters in Atlanta provides us access to some of the finest clinical, technical and analytics talent in the country,” said Shay Hurst, SVP of Human Resources, Oncology Analytics. “As we look to significantly expand our team in roles focused on data science, software engineering, clinical oncology, product management and client services, we are confident Atlanta offers the resources we need for our next stage of growth.”

Read more...
 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 3 of 37